Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156567 | 0.86 | SLC1A3 (0.34) | HTR6PTGDR2HTR1ADRD2HTR2A | |
| SCHEMBL1278067 | 0.85 | FPR1 (0.40) | PTGDR2KDM4EPOLBPTGS2 | |
| SCHEMBL1156560 | 0.83 | PTGDR2 (0.39) | HTR6PTGDR2 | |
| SCHEMBL1157051 | 0.80 | ADAMTS4 (0.39) | SHMT1POLB | |
| SCHEMBL1156157 | 0.80 | HTR6 (0.43) | HTR6L3MBTL1PTGDR2HTR1ADRD2 | |
| SCHEMBL4569735 | 0.80 | PTGDR (0.42) | HTR6PTGDR2PTGDRKMT2AMEN1 | |
| SCHEMBL1157092 | 0.80 | SLC1A3 (0.40) | PTGDR2PTGS2 | |
| SCHEMBL1156390 | 0.80 | ADAMTS4 (0.39) | — | |
| SCHEMBL1278791 | 0.79 | PTGDR2 (0.36) | PTGDR2POLBPTGS2 | |
| SCHEMBL1156706 | 0.79 | AKR1C3 (0.39) | PTGDR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | HTR6 1412/4885L3MBTL1 3593/4885PTGDR2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.